BioLife Solutions (BLFS)
NASDAQ:BLFS
Want to see BLFS full AI Analyst Report?
BLFS Stock Chart & Stats
$20.11
-$0.09(-0.33%)
At close: 4:00 PM EST
$20.11
-$0.09(-0.33%)
Day’s Range― - ―
52-Week Range$17.86 - $29.62
Previous CloseN/A
Volume44.73K
Average Volume (3M)363.00K
Market Cap
$1.22B
Enterprise Value$1.21B
Total Cash (Recent Filing)$81.00M
Total Debt (Recent Filing)$14.86M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 06, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding48,857,414
10 Day Avg. Volume392,925
30 Day Avg. Volume363,004
Financial Highlights & Ratios
PEG Ratio2.20
Price to Book (P/B)3.10
Price to Sales (P/S)12.00
P/FCF Ratio108.55
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue12.12
Enterprise Value/Gross Profit18.98
Enterprise Value/Ebitda-162.14
Forecast
1Y Price Target
$33.00Price Target Upside64.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.15
Revenue Forecast (FY)$113.71M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow absolute debt versus a sizable equity base gives BioLife durable financial flexibility. Modest leverage reduces refinancing risk, supports investment in product launches and M&A, and provides a cushion to absorb operational hiccups while pursuing growth and margin recovery.
BPM Franchise LeadershipA dominant position in biopreservation media, deep embedment in approved therapies and high share in later-stage trials create durable demand. This structural foothold supports recurring consumable revenue, long validation cycles that raise switching costs, and predictable multi-year pipeline visibility.
Improving Cash Generation And MarginsRecent positive operating cash flow and stable mid‑60s gross margins demonstrate improving cash conversion and core profitability. This trend, coupled with healthy cash balances, gives time to fix operational issues, fund commercialization of new products, and pursue selective investments without immediate capital raises.
Bears Say
Customer And Product ConcentrationHigh dependence on one product category and a small set of customers raises structural revenue volatility and customer bargaining risk. Loss or volume reduction at a major customer, or slower clinical/commercial adoption patterns, could materially affect top-line and margin consistency over the medium term.
Bag Yield / Manufacturing RiskManufacturing yield and scrap issues on bag products are a structural operational risk that compress gross margins until resolved. Because consumables margins drive profitability, extended remediation timelines (management cites Q4 2026–Q1 2027) could delay durable margin expansion and weaken operating leverage.
FCF Volatility & Near-term Working-capital PressureWhile liquidity is adequate, recent cash decline, working-capital swings and near-term debt maturities introduce short‑term funding risk. Persistent free‑cash‑flow volatility reduces optionality for investments and increases reliance on execution to convert operating improvements into sustainable cash generation.
BioLife Solutions News
BLFS FAQ
What was BioLife Solutions’s price range in the past 12 months?
BioLife Solutions lowest stock price was $17.86 and its highest was $29.62 in the past 12 months.
What is BioLife Solutions’s market cap?
BioLife Solutions’s market cap is $1.22B.
When is BioLife Solutions’s upcoming earnings report date?
BioLife Solutions’s upcoming earnings report date is Aug 06, 2026 which is in 66 days.
How were BioLife Solutions’s earnings last quarter?
BioLife Solutions released its earnings results on May 07, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.017 by $0.003.
Is BioLife Solutions overvalued?
According to Wall Street analysts BioLife Solutions’s price is currently Undervalued.
Does BioLife Solutions pay dividends?
BioLife Solutions does not currently pay dividends.
What is BioLife Solutions’s EPS estimate?
BioLife Solutions’s EPS estimate is 0.03.
How many shares outstanding does BioLife Solutions have?
BioLife Solutions has 48,857,414 shares outstanding.
What happened to BioLife Solutions’s price movement after its last earnings report?
BioLife Solutions reported an EPS of $0.02 in its last earnings report, beating expectations of $0.017. Following the earnings report the stock price went down -4.671%.
Which hedge fund is a major shareholder of BioLife Solutions?
Currently, no hedge funds are holding shares in BLFS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioLife Solutions Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (64.10% Upside)
$33.00 (64.10% Upside)
Blogger Sentiment
Bullish
BLFS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 61.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $30.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.00%
12-Months-Change
Fundamentals
Return on Equity
-2.91%
Trailing 12-Months
Asset Growth
1.46%
Trailing 12-Months
Company Description
BioLife Solutions
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
BLFS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a constructive growth story highlighted by strong top-line performance (Q1 revenue +25%), improved profitability in absolute dollars (adjusted EBITDA up ~15%, GAAP net income positive), clear market leadership in BPM with robust pipeline visibility, and reaffirmed full-year guidance. Key operational challenges—most notably bag yield/scrap issues that compressed gross margin and adjusted EBITDA margin, rising operating expenses tied to R&D and severance, short-term cash/working capital pressures, and customer/product concentration—represent meaningful near-term risks but are described as manageable and temporary by management. Given the combination of durable demand drivers, strategic initiatives (product launches, cross-sell opportunities) and a solid balance sheet, the positive growth and leadership signals outweigh the transitory operational headwinds in management's view.View all BLFS earnings summariesBLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services
BLFS Stock 12 Month Forecast
Average Price Target
$33.00
▲(64.10% Upside)
Technical Analysis
Azenta
―
Staar Surgical
―
Pulse Biosciences
―
Sanara MedTech
―
Kestra Medical Technologies Ltd.
―
Ownership Overview
16.21% Insiders
31.81% Mutual Funds
10.65% Other Institutional Investors
23.64% Public Companies and
Individual Investors